6540-33-6

Usage

Uses

Used in Pharmaceutical Industry:
Cyclobutyl-acetic acid is used as a key intermediate in the synthesis of pharmaceuticals for its role in creating compounds with specific medicinal properties. Its structural features allow for the development of drugs that can target various biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, cyclobutyl-acetic acid is utilized as a building block in the creation of agrochemicals, potentially contributing to the development of new pesticides or other agricultural chemicals that can improve crop yields and protect against pests.
Used in Research and Development:
Cyclobutyl-acetic acid is employed as a subject of research for potential therapeutic applications, given its anti-inflammatory and analgesic effects. Scientists are exploring its properties to discover new uses in medicine and other fields.
Used in Medicinal Chemistry:
As a carboxylic acid with a unique cyclobutyl group, cyclobutyl-acetic acid is used in medicinal chemistry to develop novel drug candidates. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacokinetic properties.

InChI:InChI=1/C6H10O2/c7-6(8)4-5-2-1-3-5/h5H,1-4H2,(H,7,8)

Upstream product

• 4426-03-3 cyclobutyl acetonitrile 
• 6540-31-4 2-cyclobutylacetaldehyde 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 4415-82-1 cyclobutanemethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 124-38-9 carbon dioxide 
• 5006-22-4 Cyclobutanecarbonyl chloride 

Downstream Products

• 301186-27-6 (R)-4-benzyl-3-(2-cyclobutylacetyl)oxazolidin-2-one 
• 36206-72-1 2-cyclobutylethyl 4-methylbenzenesulfonate 
• 1124212-25-4 N-tert-butyl-3-((4-(4-(2-cyclobutylacetamido)benzoyl)piperazin-1-yl)methyl)benzamide 2,2,2-trifluoroacetate 
• 1297551-48-4 (+/-)-tert-butyl 3-(3-bromo-4-chlorophenyl)-2-cyclobutylpropanoate 
• 909717-49-3 (S)-2-Cyclobutyl-pent-4-enoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 909717-47-1 (S)-4-Benzyl-3-((S)-2-cyclobutyl-pent-4-enoyl)-oxazolidin-2-one 
• 4415-74-1 2-cyclobutylethanol 

Relevant academic research and scientific papers

Synthesis of novel shikonin derivatives and pharmacological effects of cyclopropylacetylshikonin on melanoma cells

Despite much research in the last centuries, treatment of malignant melanoma is still challenging because of its mostly unnoticeable metastatic spreading and aggressive growth rate. Therefore, the discovery of novel drug leads is an important goal. In a previous study, we have isolated several shikonin derivatives from the roots of Onosma paniculata Bureau & Franchet (Boraginaceae) which evolved as promising anticancer candidates. β,β-Dimethylacrylshikonin (1) was the most cytotoxic derivative and exhibited strong tumor growth inhibitory activity, in particular, towards melanoma cells. In this study, we synthesized eighteen novel shikonin derivatives in order to obtain compounds which exhibit a higher cytotoxicity than 1. We investigated their cytotoxic potential against various melanoma cell lines and juvenile skin fibroblasts. The most active compound was (R)-1-(1,4-dihydro-5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl cyclopropylacetate (cyclopropylacetylshikonin) (6). It revealed significant stronger tumor growth inhibitory activity towards two melanoma cell lines derived from metastatic lesions (WM164 and MUG-Mel2). Further investigations have shown that 6 induced apoptosis caspase-dependently, increased the protein levels of cleaved PARP, and led to double-stranded DNA breaks as shown by phosphorylation of H2AX. Cell membrane damage and cell cycle arrest were not observed.

PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or lnterleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS

The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]- pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties

A systematic examination of the central aromatic portion of the lead (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(1′H-spiro[indene-1,4′-piperidin]-1′-yl)butanamide (9) led to the discovery of a novel class of CCR2 receptor antagonists, which carry small alicyclic groups such as cyclopropyl, cylobutyl, or cyclopropylmethyl attached at C2 of the carbon backbone. The most potent compound discovered, namely (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-cyclopropyl-4-[(1R,3′R)-3′-methyl-1′H-spiro[indene-1,4′-piperidin]-1′-yl]butanamide (29), showed very high binding affinity (IC50 = 4 nM, human monocyte) and excellent selectivity toward other related chemokine receptors. The excellent pharmacokinetic profile of this new lead compound allows for extensive in vivo evaluation.

CARBOXAMIDE INHIBITORS OF TGFB

Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C- 4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFB activity.

INHIBITORS OF TFGβ

Certain appropriately substituted forms of pyrimidine and triazine are useful in the treatment to conditions associated with enhanced TGFβ activity.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Unusual products from dirhodium tetraacetylate-catalyzed decomposition of diazoacetylcycloalkanes

Rh2(OAc)4-assisted decompositions of diazoacetylcycloalkanes are shown to yield cycloalkylacetic acids (Wolff rearrangement), unexpected cycloalkylcarboxylic acids and bicyclic ketones (intramolecular C-H bond insertion). Rh2(OCOF3)4-promoted reactions, on the other hand, have furnished bicyclic ketones and ketene dimers.